VIR — Vir Biotechnology Income Statement
0.000.00%
Last trade - 00:00- $1.45bn
- $980.49m
- $68.56m
Annual income statement for Vir Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,095 | 1,616 | 86.2 | 74.2 | 68.6 |
| Cost of Revenue | |||||
| Gross Profit | 1,030 | 1,469 | 83.4 | 73.4 | 68.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 675 | 783 | 770 | 661 | 548 |
| Operating Profit | 421 | 833 | -684 | -587 | -479 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 550 | 754 | -628 | -523 | -438 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 529 | 516 | -615 | -522 | -438 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 529 | 516 | -615 | -522 | -438 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 529 | 516 | -615 | -522 | -438 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.96 | 3.83 | -4.59 | -3.66 | -3.16 |